【ProductName】 |
SLC27A5 Antibody Blocking Peptide |
|
---|---|---|
【Cat NO.】 |
K110168P-Ag |
|
【Source】 |
Synthetic |
|
【Storage】 |
Store at -20℃,2 years.Avoid freeze/thaw cycles. |
|
【Appearance】 |
Lyophilized powder |
|
【Swiss Prot】 |
Q9Y2P5 |
|
【Gene ID】 |
10998 |
|
【Application】 |
Blocking Peptide of K110168P Antibody |
|
【Purification】 |
HPLC |
|
【Activity】 |
Not tested |
|
【Note】 |
Please allow the product to equilibrate to room temperature in a dry environment before opening the packaging. |
|
Acyl-CoA synthetase that catalyzes the activation of bile acids via formation of bile acid CoA thioesters which is necessary for their subsequent conjugation with glycine or taurine (PubMed:10749848, PubMed:11980911). Both primary bile acids (cholic acid and chenodeoxycholic acid) and secondary bile acids (deoxycholic acid and lithocholic acid) are the principal substrates (PubMed:10749848, PubMed:11980911). Also exhibits acyl CoA synthetase activity that activates very long-chain fatty acids (VLCFAs) by catalyzing the formation of fatty acyl-CoA (PubMed:10479480). In vitro, also activates 3-alpha,7-alpha,12-alpha-trihydroxy-5-beta-cholestanate (THCA), the C27 precursor of cholic acid deriving from the de novo synthesis from cholesterol (PubMed:11980911). Exhibits long-chain fatty acids (LCFA) transport activity (PubMed:20530735). Plays an important role in hepatic fatty acid uptake and bile acid reconjugation and recycling but not in de novo synthesis of bile acids (By similarity).